276 Preclinical and clinical safety profile of SPL84, an antisense oligonucleotide for treatment of people with cystic fibrosis carrying the 3849 +10 Kb C ->T mutation, supporting Phase 2 study initiation
DOI:
10.1016/s1569-1993(24)01116-0
Publication Date:
2024-09-04T09:43:43Z
AUTHORS (7)
ABSTRACT
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....